Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Brain Tumor

Trial Name: Name of Trial: A Randomized Phase II Trial of Concurrent Bevacizumab And Re-Irradiation Versus Bevacizumab Alone As Treatment For Recurrent Glioblastoma.

Protocol ID: RTOG 1205

Eligibility:

Eligibility:

  • Must have histologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc.).  Patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made.
  • Patient must be 18 years of age and older.
  • Must meet required laboratory values.
  • Women must not be pregnant or nursing.
  • Patients must be willing to practice effective contraception while on study treatment and 6 months after (women of childbearing potential and men).
  • No prior therapy with an inhibitor of VEGF or VEGFR (including bevacizumab).
  • No prior history of allergic reaction to bevacizumab.

No prior history of hypertensive crisis or hypertensive encephalopathy.

Enrollment: • About 178 people will take part in this study at several medical centers.

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope that adding radiation to bevacizumab will be more useful against cancer compared to bevacizumab alone, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about combining bevacizumab and radiation as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Jul 19, 2013

Updated: Oct 16, 2014

« Return to Trials